Rendering

Component: (Network and Table)
Network
025 - Disclosure - Note 6 - STOCKHOLDERS' EQUITY (Tables)
(http://www.biostarpharmaceuticals.com/role/Note6STOCKHOLDERSEQUITYTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001418133 (http://www.sec.gov/CIK)
Stockholders' Equity Note [Abstract]Period [Axis]
2015-01-01 - 2015-12-31
Stockholders' Equity Note [Abstract]
 
Schedule of Stockholders Equity [Table Text Block]
On February 4, 2016, the Company effectuated a one-for-seven reverse split of its common stock; the Company’s stockholder’s equity, information on number of shares and (loss) earnings per share has been retroactively restated to the first period presented.

For the year ended December 31, 2014
 
Shares issued
 
Value
 
i. issued to selected investors through placement agent, at $17.43 per share less financing cost
   
235,714
   
$
3,862,533
 
ii. issued to employees based on 2013 Incentive Stock Plan, valued at $10.08 per share
   
164,285
     
1,656,000
 
Total common stock issued during the year ended December 31, 2014
   
399,999
   
$
5,518,533
 
  
Schedule of Allocated Equity and Liability [Table Text Block]
The amount of $3,862,533 relating to item (i) above is allocated to the following equity and liability:

Common stock
  $
235
 
Warrants liability - Note 6(b)
   
960,894
 
Additional paid-in-capital
   
2,901,404
 
     
3,862,533
 
  
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
The following table summarizes the Company’s outstanding warrants as of December 31, 2015 and 2014.

         
Outstanding as at December 31,
 
Expiry date
 
Exercise Price
   
2015
   
2014
 
June 30, 2014
 
$
57.54
     
-
     
-
 
March 12, 2017 *
   
22.61
     
108,428
     
108,428
 
             
108,428
     
108,428
 
* The Company’s recurring fair value measurements at December 31, 2015 were as follows: 
  
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]
* The Company’s recurring fair value measurements at December 31, 2015 were as follows:

   
Fair Value as of
 December 31, 2015
 
Significant
Unobservable
Inputs
 (Level 3)
 
Liabilities:
               
Warrants expiring March 2017
 
$
59,202
   
$
59,202
 
  
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
The following tables summarize activities for the Company’s options for the years ended December 31, 2015 and 2014.

For the Year Ended December 31, 2015
           
         
Weighted Average
 
   
Number of options
   
Exercise Price ($)
   
Remaining Life (years)
 
Outstanding at beginning of period
   
9,143
     
34.79
     
1.54
 
Granted, exercised or forfeited
   
-
     
-
     
-
 
Expired
   
(2,381
)
   
-
     
-
 
Outstanding at end of period
   
6,762
     
26.39
     
0.54
 
For the Year Ended December 31, 2014
           
         
Weighted Average
 
   
Number of options
   
Exercise Price ($)
   
Remaining Life (years)
 
Outstanding at beginning of period
   
55,174
     
54.67
     
1.08
 
Granted, exercised or forfeited
   
-
     
-
     
-
 
Expired
   
(46,031
)
   
58.59
     
-
 
Outstanding at end of period
   
9,143
     
34.79
     
1.54